Application of sulfoximines in medicinal chemistry from 2013 to 2020

In recent years, interest in sulfoximine chemistry has been greatly increased. For example, at least three sulfoximine containing drugs BAY 1143572, BAY 1251152 and AZD6738 have entered the clinic. Despite the increasing interest in sulfoximines and their chemistry, the routine application of this structure in drug discovery is still hampered due to limited experience in physicochemical and in vitro parameters of sulfoximines. Therefore, we reviewed all relevant articles from 2013 to the present in terms of potency and pharmacokinetic properties in order to support the addition of the sulfoximine component to the toolbox of medicinal chemists.

 

Comments:

It's great to hear that there is increasing interest in sulfoximine chemistry and its potential applications in drug discovery. It seems like you have undertaken a comprehensive review of relevant articles from 2013 to the present to gain insights into the potency and pharmacokinetic properties of sulfoximines. This kind of review is valuable in supporting the addition of sulfoximine components to the toolbox of medicinal chemists. By compiling and analyzing this information, you can contribute to a better understanding of the physicochemical and in vitro parameters of sulfoximines, which will be helpful for future drug development efforts.

Sulfoximines have shown promise in the development of several drugs, including BAY 1143572, BAY 1251152, and AZD6738, which have entered clinical trials. These examples highlight the potential of sulfoximine-containing compounds in therapeutic applications. However, as you mentioned, limited experience with the physicochemical and in vitro parameters of sulfoximines has hindered their routine application in drug discovery.

By reviewing articles published between 2013 and the present, you aim to address this limitation and provide medicinal chemists with a more comprehensive understanding of sulfoximines' properties. This information will assist researchers in designing and optimizing sulfoximine-based compounds for enhanced potency and improved pharmacokinetic profiles.

Overall, your efforts to review and consolidate the available literature on sulfoximines will contribute to expanding the knowledge base in this field and facilitate future drug discovery endeavors.

Related Products

Cat.No.	Product Name	Information
S8730	Enitociclib (BAY 1251152)	Enitociclib (BAY 1251152) is a potent PTEFb/CDK9 inhibitor with an IC50 value of 3 nM for CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins.

Related Targets

CDK